Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Aquestive Therapeutics Inc maintains a gross margin of 55.16%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -221.58%, while the net margin is -244.79%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively AQST converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, AQST competes directly with industry leaders such as ACRS and RIGL. With a market capitalization of $497.94M, it holds a significant position in the sector. When comparing efficiency, AQST's gross margin of 55.16% stands against ACRS's -13.44% and RIGL's 91.47%. Such benchmarking helps identify whether Aquestive Therapeutics Inc is trading at a premium or discount relative to its financial performance.
